The collaboration grants Genentech exclusive rights to Sangamo’s zinc finger repressors aimed at the tau gene, which is implicated in Alzheimer’s disease, and an undisclosed neurology target. Sangamo’s adeno-associated virus (AAV) capsid, STAC-BBB, capable of crossing the blood-brain barrier to deliver therapies to the central nervous system, is also included in the licensing agreement.
Sangamo will be responsible for completing the technology transfer and conducting some preclinical activities, while Genentech will oversee clinical development, regulatory interactions, manufacturing, and global commercialization of these assets.
This partnership comes at a critical time for Sangamo, which has been struggling financially. Prior to this deal, Sangamo had enough cash reserves to last only until the third quarter of 2024, and a recent Seeking Alpha report suggested the company was on the brink of bankruptcy. The announcement of the Genentech deal caused Sangamo’s stock to surge by over 40%.
Sangamo CEO Sandy Macrae expressed optimism about the partnership, emphasizing the potential of their zinc finger technology and the STAC-BBB capsid to address significant challenges in central nervous system therapeutics. Despite the financial boost from this deal, Sangamo continues to seek additional partnerships, particularly for its Fabry disease candidate, isaralaggene civaparvovec, which has received FDA Fast Track designation.
This new agreement with Genentech marks Sangamo’s first major deal since 2020, when a collaboration with Biogen, worth $350 million upfront, was established but later discontinued. Recently, there has been renewed hope for Sangamo with positive Phase III results for their Pfizer-partnered hemophilia A gene therapy, giroctocogene fitelparvovec, which could provide substantial milestone payments and royalties if approved.
Roche’s commitment to overcoming the challenges of developing Alzheimer’s treatments remains strong, as demonstrated by this new venture with Sangamo. This partnership provides a crucial financial lifeline to Sangamo while leveraging their innovative genomic technologies to potentially make significant strides in the treatment of neurodegenerative diseases.
https://www.biospace.com/deals/cash-strapped-sangamo-gets-lifeline-from-genentech-in-potential-1-9b-neuro-deal
https://www.biopharmadive.com/news/sangamo-roche-genentech-alzheimers-tau-gene-drugs/723444/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
